0001680581-17-000001.txt : 20170510
0001680581-17-000001.hdr.sgml : 20170510
20170510100741
ACCESSION NUMBER: 0001680581-17-000001
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20170510
DATE AS OF CHANGE: 20170510
EFFECTIVENESS DATE: 20170510
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Fulcrum Therapeutics, Inc.
CENTRAL INDEX KEY: 0001680581
IRS NUMBER: 474839948
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-286393
FILM NUMBER: 17828828
BUSINESS ADDRESS:
STREET 1: ONE KENDALL SQUARE
STREET 2: BUILDING 700, SUITE B7102
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-651-8851
MAIL ADDRESS:
STREET 1: ONE KENDALL SQUARE
STREET 2: BUILDING 700, SUITE B7102
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
D
1
primary_doc.xml
X0707
D
LIVE
0001680581
Fulcrum Therapeutics, Inc.
ONE KENDALL SQUARE
BUILDING 700, SUITE B7102
CAMBRIDGE
MA
MASSACHUSETTS
02139
617-651-8851
DELAWARE
None
None
Corporation
true
2015
Robert
Gould
One Kendall Square
Building 700, Suite B7102
Cambridge
MA
MASSACHUSETTS
02139
Executive Officer
Director
Mark
Levin
One Kendall Square
Building 700, Suite B7102
Cambridge
MA
MASSACHUSETTS
02139
Director
James
Geraghty
One Kendall Square
Building 700, Suite B7102
Cambridge
MA
MASSACHUSETTS
02139
Director
James
Collins
One Kendall Square
Building 700, Suite B7102
Cambridge
MA
MASSACHUSETTS
02139
Director
Alan
Ezekowitz
One Kendall Square
Building 700, Suite B7102
Cambridge
MA
MASSACHUSETTS
02139
Director
Biotechnology
Decline to Disclose
- 06b
false
2017-04-28
false
true
false
0
5000000
5000000
0
false
1
0
0
0
false
Fulcrum Therapeutics, Inc.
/s/ Robert Gould
Robert Gould
President and Chief Executive Officer
2017-05-10